Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
The injectable obesity medications Semaglutide 2.4 mg, a selective GLP-1 receptor agonist, produces robust and durable weight loss of approximately 1516% over 68 weeks ( Tirzepatide, a dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonist, delivers even greater weight loss, exceeding 20% at the highest dose in pivotal trials ( Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, represents a further step in efficacy, with 24.2% weight loss achieved within 48 weeks in phase 2 studies ( Survodutide, an oxyntomodulin analogue, achieved clinically meaningful weight loss ( Table 2
But who are these medications best suited for
Before I started fasting I ran 5 miles most mornings
Other GLP-1 agonist drugsa class that includes Mounjaro and Zepbound, which have the same active ingredienthave also been approved to reduce the risk of heart attack and stroke in overweight people
